Hold IBM with conditional 15% starter trigger post-Jackson Hole, convert stop to daily-close invalidation, preserve 33%/33% scale-in framework, and add covered-call overlay
The consensus Hold is correct given the improving technical setup (MACD histogram +1.11, RSI 53.24, +9.34% off July $204 low) balanced against unresolved structural risks ($74.6B goodwill at 49% of assets, -$54.10B tangible book value, sub-1 current ratio) and binary macro catalysts (Jackson Hole, Sept FOMC, Q3 earnings). The conditional 15% starter trigger post-Jackson Hole captures asymmetric R/R (downside ~2% to $233 stop vs upside ~3.5% to $243 trigger) without front-running binary risk. Combined with the 33%/33% scale-in at $243 and $261, maximum committed weight at full confirmation is 81% of target. The covered-call overlay at $245-$250 adds 1.5-2.5% premium income that prevents drift-purgatory exposure and structures the Hold as an active yield-and-catalyst position rather than passive drift. The $233 daily-close invalidation (not intraday) appropriately requires genuine loss of the 10-day EMA/Bollinger middle band on a confirmed basis rather than ordinary noise on $7.73 ATR.
| Position | Action |
|---|---|
| Jackson Hole clears Aug 28 without hawkish shock AND IBM closes Aug 28-29 above $233 on confirmed daily closes | Deploy 15% of target weight as starter position |
| IBM closes above $243 (50 SMA) on volume >6M with RSI >55 and expanding MACD histogram, PLUS Q3 2026 beat-and-raise with HashiCorp contribution disclosure and no goodwill impairment | Upgrade to Overweight (33% of target weight) |
| IBM closes above $261 (200 SMA) on volume >6M with 200 SMA flattening confirming structural trend reversal | Upgrade to Buy (33% of target weight) |
| IBM closes above $243 on volume >6M with RSI >55 and expanding MACD histogram (50 SMA reclaim) | Upgrade to Overweight |
The bear's technical arguments miss the fundamental transformation; IBM offers asymmetric reward with downside cushioned by 6.4% FCF yield and 2.94% dividend, upside driven by revenue reacceleration, Arm mainframe breakthrough, and mean reversion from the 28% drawdown.
| Indicator | Value | Signal |
|---|---|---|
| close_10_ema | $233.94 | bullish |
| close_50_sma | $243.03 | bearish |
| close_200_sma | $261.03 | bearish |
| macd_line | -0.96 | bullish |
| macd_signal | -2.07 | neutral |
| macd_histogram | +1.11 | bullish |
| rsi | 53.24 | neutral |
| boll_ub | $241.95 | bearish |
| boll_mid | $233.30 | bullish |
| boll_lb | $224.64 | bearish |
| atr | $7.73 (3.2% of price) |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Upgrade to Overweight
Revenue reacceleration underway with strong earnings growth trajectory
↩ rebuts: “Bear's 'slow-growth legacy name' characterization”
EV: +23% (target $295) · concedes: Stock remains 8.5% below 200-day SMA at $261.03; MACD still negative at -0.96 (though improved 93%); YTD performance of -19.66%; Software segment showed volatility
IBM's technical setup shows intact structural downtrend with declining moving averages, MACD below zero, and resistance at $243.03; revenue reacceleration is a one-quarter phenomenon against a soft comp; balance sheet has $74.6B goodwill, negative tangible book value, and sub-1 current ratio; and catalysts are narrative rather than near-term P&L impact.
EV: $210 (16x multiple compression) · concedes: FCF yield of 6.4% is attractive on paper; $6.3B in annual dividends provides income support; One quarter of +7.8% YoY growth is better than continued decline; FCF generation of $14.5B LTM demonstrates cash generation capability
→ vs conservative: 200-day SMA declining and stock 8.5% below it is not a warning sign but the definition of mean reversion at the inflection point — waiting for it to flatten means buying at $270-280
→ vs conservative: Catching a falling knife applies to buying at $332 on the way down, not buying at $238.79 with +7.8% revenue growth and a 6.4% FCF yield after stock already bounced +17% from July lows
→ vs neutral: Waiting for 50-day SMA confirmation means paying higher prices for the same thesis — every prior rejection of $243.03 makes eventual breakout more violent, potentially to $250+ before confirmation arrives
→ vs neutral: The 30% probability of September rate hike is not a risk for IBM — it's a low-beta dividend payer where soft landing with hawkish tilt is the best possible macro backdrop
→ vs neutral: Markets price probabilities, not analytical symmetry — probability-weighted outcome is bullish given improving trend, stacked catalysts, compelling valuation, supportive macro, and muted sentiment
| neutral |
Support: 233.3 · 233.94 · 224.64 | Resistance: 241.95 · 243.03 · 261.03
IBM exhibits short-term recovery within a bearish medium- and long-term framework. The stock closed at $238.79, trading above the 10-day EMA ($233.94) and Bollinger middle band ($233.30), with MACD showing improving momentum (line -0.96 above signal -2.07, histogram +1.11). However, price remains below the declining 50-day SMA ($243.03) and well below the 200-day SMA ($261.03), with MACD still below zero. The ATR of $7.73 indicates high volatility requiring ATR-adjusted position sizing. The critical decision zone is $241.95–$243.03; a sustained close above would support a bullish upgrade, while a close below $233.30–$233.94 would weaken the rebound setup.
Market Cap
$224.97B
TTM P/E
21.59x
Forward P/E
18.14x
PEG Ratio
2.39
P/B
6.53x
EPS (TTM)
$11.06
Forward EPS
$13.16
Dividend Yield
2.94%
Beta
0.705
52-Week High
$332.46
52-Week Low
$199.19
50-Day MA
$244.94
200-Day MA
$264.88
Revenue Q2 2026 (Jun)
$17.162B
Revenue Q1 2026 (Mar)
$15.917B
Revenue Q4 2025 (Dec)
$19.687B
Revenue Q3 2025 (Sep)
$16.331B
Revenue Q2 2025 (Jun)
$16.977B
Gross Margin
57.7%
Operating Margin
16.6%
Net Income Q2 2026
$2.165B
Net Income Q1 2026
$1.216B
Operating Margin TTM
16.55%
Net Margin TTM
15.52%
ROE
34.46%
ROA
5.30%
EBITDA TTM
$16.47B
Gross Profit TTM
$40.14B
Net Income Q4 2025
$5.6B
Normalized Q4 EPS
$3.80
Total Assets
$152.10B
Total Liabilities
$117.56B
Stockholders' Equity
$34.45B
Total Debt
$65.27B
Net Debt
$54.82B
Cash & Equivalents
$7.17B
Goodwill
$74.60B
Intangibles
$13.95B
Tangible Book Value
-$54.10B
Working Capital
-$7.51B
Current Ratio
0.79
Debt-to-Equity
188.97
Operating Cash Flow Q2 2026
$2.597B
Free Cash Flow Q2 2026
$2.214B
CapEx Q2 2026
$0.383B
Dividends Q2 2026
$1.590B
LTM Operating Cash Flow
~$16.59B
LTM Free Cash Flow
~$14.47B
FCF Yield
~6.4%
Debt Repaid Q2 2026
$4.21B
M&A Q1 2026
$10.46B
New Debt Issued Q1 2026
$7.44B
Implied Current Price
~$239
Strengths
Concerns
IBM presents a value-and-yield thesis with improving fundamentals: Q2 2026 revenue reaccelerated to +7.8% YoY (strongest in years) driven by Red Hat, HashiCorp, and watsonx, while forward P/E of 18.14x and FCF yield of ~6.4% offer attractive valuations. However, the stock trades ~28% below its 52-week high and below its 200-day MA ($264.88), reflecting weak technical sentiment despite a 2.94% dividend yield and growing equity (+25% YoY). The negative tangible book value (-$54.1B) from heavy M&A activity limits asset cushion, and $65.27B in debt requires continued deleveraging.
Macro: Soft landing with hawkish-tilt risk; rate-cut odds collapsing (Polymarket: 88% no cuts in 2026, up ~2.2pp on week, $7.6M volume), but no recession priced (US recession by YE2026: 8%, UK 11%, Japan 20%). September 16, 2026 FOMC meeting pricing: 68% hold, 30% hike +25 bps (up 3pp on week, $10.7M volume), 1% cut. Inflation-above-5% in 2026 priced at only 8%, suggesting bond market not bracing for re-acceleration. This environment benefits IBM's value-style profile (dividend payer, ~$234 stock, post-28% drawdown) as a forgotten-quality, cyclically-recovering tech name.